Company Overview of Redbiotec AG
Redbiotec AG develops and produces multiprotein assemblies. It specializes in producing virus-like particles (VLP), various types of protein complexes and single proteins, and VLP-based vaccines against various infectious diseases. The company’s products are used in complex drug target, structural studies, target validation, antibody generation, biopharmaceutical, and VLP applications. Redbiotec AG was founded in 2006 and is based in Schlieren, Switzerland.
Founded in 2006
Key Executives for Redbiotec AG
Chief Executive Officer and Director
Compensation as of Fiscal Year 2014.
Redbiotec AG Key Developments
Redbiotec AG Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Redbiotec AG Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Redbiotec and GE Healthcare Collaborate
Jul 30 14
Redbiotec has successfully applied its unique expertise and innovative technology platform to complete a collaborative program with GE Healthcare Life Sciences. Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of cytomegalovirus-like particles. Results from the study have recently been published, further substantiating the value of the Redbiotec rePAX platform for the development and production of new vaccines against cytomegalovirus (CMV). Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is effectively applied to both in-house and external co-development programs, supporting the company’s mission to discover and develop novel, effective vaccines against the highly prevalent influenza and herpes viruses.
Redbiotec and TeselaGen Announce Joint Venture
Sep 3 13
Redbiotec and TeselaGen Biotechnology Inc. have announced a joint venture to build a scalable, integrated, rapid design and rapid prototyping infrastructure for the creation of a library for Herpesvirus vaccine development. This library will enable new concepts for vaccines against Herpesviruses and the optimization of existing vaccine candidates.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 5, 2015
Most Searched Private Companies
Sponsored Financial Commentaries